相似文献
1
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.
Cells. 2019 Jan 11;8(1):43. doi: 10.3390/cells8010043.
2
Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Cancer Lett. 2017 Jul 1;397:133-143. doi: 10.1016/j.canlet.2017.03.022. Epub 2017 Mar 18.
3
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1.
4
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13.
5
Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Urol Oncol. 2016 Aug;34(8):356-67. doi: 10.1016/j.urolonc.2015.11.003. Epub 2015 Dec 17.
6
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Endocr Relat Cancer. 2016 Dec;23(12):T179-T197. doi: 10.1530/ERC-16-0422. Epub 2016 Oct 31.
7
Molecular model for neuroendocrine prostate cancer progression.
BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24.
8
Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29.
9
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Cancer Treat Rev. 2017 Jun;57:16-27. doi: 10.1016/j.ctrv.2017.04.008. Epub 2017 May 8.
10
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
引用本文的文献
1
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.
Cell Death Dis. 2024 Jun 19;15(6):433. doi: 10.1038/s41419-024-06837-w.
2
Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Curr Oncol Rep. 2024 May;26(5):488-495. doi: 10.1007/s11912-024-01509-6. Epub 2024 Apr 9.
3
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy.
Biomedicines. 2023 Apr 6;11(4):1105. doi: 10.3390/biomedicines11041105.
4
Cancer Stemness/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target.
Int J Mol Sci. 2022 Nov 29;23(23):14917. doi: 10.3390/ijms232314917.
5
A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer.
Front Endocrinol (Lausanne). 2022 Oct 21;13:1037099. doi: 10.3389/fendo.2022.1037099. eCollection 2022.
6
Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer.
Asian J Androl. 2023 May-Jun;25(3):296-308. doi: 10.4103/aja202263.
7
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
Biomedicines. 2022 Jun 15;10(6):1416. doi: 10.3390/biomedicines10061416.
8
Large-Scale Transcriptome Data Analysis Identifies KIF2C as a Potential Therapeutic Target Associated With Immune Infiltration in Prostate Cancer.
Front Immunol. 2022 Jun 3;13:905259. doi: 10.3389/fimmu.2022.905259. eCollection 2022.
9
The functional roles of the circRNA/Wnt axis in cancer.
Mol Cancer. 2022 May 5;21(1):108. doi: 10.1186/s12943-022-01582-0.
10
Molecular Mechanisms of Coffee on Prostate Cancer Prevention.
Biomed Res Int. 2022 Apr 22;2022:3254420. doi: 10.1155/2022/3254420. eCollection 2022.
本文引用的文献
1
Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Expert Opin Emerg Drugs. 2018 Dec;23(4):271-282. doi: 10.1080/14728214.2018.1547707. Epub 2018 Nov 28.
2
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
3
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Front Oncol. 2018 Sep 24;8:397. doi: 10.3389/fonc.2018.00397. eCollection 2018.
4
Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers.
Nat Commun. 2018 Oct 4;9(1):4080. doi: 10.1038/s41467-018-06177-2.
5
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Clin Cancer Res. 2019 Jan 1;25(1):52-63. doi: 10.1158/1078-0432.CCR-18-1589. Epub 2018 Sep 17.
6
Alternative splicing in prostate cancer.
Nat Rev Clin Oncol. 2018 Nov;15(11):663-675. doi: 10.1038/s41571-018-0085-0.
7
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Oncogene. 2019 Jan;38(1):17-32. doi: 10.1038/s41388-018-0414-x. Epub 2018 Aug 2.
8
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
9
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.
Expert Rev Mol Diagn. 2018 Jul;18(7):645-655. doi: 10.1080/14737159.2018.1490179. Epub 2018 Jun 29.
10
Epigenetic Regulation in Prostate Cancer Progression.
Curr Mol Biol Rep. 2018;4(2):101-115. doi: 10.1007/s40610-018-0095-9. Epub 2018 Apr 18.
Zotero 插件
